Differential diagnosis of systemic connective tissue diseases. Systemic lupus erythematosus. Antiphospholipid syndrome.

1. Devadharshini Rajendran

2. Sandhiya Sureshkumar

3. Athisesan Venkatesh

4. Rohit Dongre

5. Poorvaja Kannan

6. Musaeva Begaiym

(Student, International Medical Faculty, Osh State University, Kyrgyzstan)

(Student, International Medical Faculty, Osh State University, Kyrgyzstan)

(Student, International Medical Faculty, Osh State University, Kyrgyzstan)

(Student, International Medical Faculty, Osh State University, Kyrgyzstan)

(Student, International Medical Faculty, Osh State University, Kyrgyzstan)

(Teacher, International Medical Faculty, Osh State University, Kyrgyzstan)

ABSTRACT

Systemic connective tissue diseases (SCTDs) constitute a heterogeneous group of chronic autoimmune disorders characterized by immune-mediated inflammation affecting multiple organ systems. The overlap of clinical manifestations, serological markers, and pathological findings often makes accurate diagnosis challenging, particularly in early disease stages. Among these disorders, systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) present unique diagnostic complexities due to their protean manifestations and frequent coexistence. This article provides a comprehensive and clinically oriented discussion of the differential diagnosis of systemic connective tissue diseases, with a detailed emphasis on SLE and APS. Through systematic analysis of clinical features, immunological profiles, laboratory parameters, and imaging findings, this review highlights distinguishing features that aid in differentiation from other rheumatological, infectious, and hematological conditions. The role of classification criteria, evolving biomarkers, and multidisciplinary evaluation is critically examined. Understanding these differential aspects is essential for timely diagnosis, appropriate treatment, and prevention of irreversible organ damage

Introduction

The differential diagnosis of systemic connective tissue diseases centers on distinguishing systemic lupus erythematosus (SLE) from antiphospholipid syndrome (APS), while acknowledging their substantial overlap and shared pathogenic pathways. The articles, presented in chronological order, illuminate how APS and SLE intersect, diverge, and influence clinical outcomes across vascular, thrombotic, and neuropsychiatric domains, informing diagnostic classification and management strategies.

(Franco et al., 2014) frame the coexistence of APS and SLE as a clinically meaningful overlap within Colombian patients, underscoring that SLE carries vascular risks and accelerated atherosclerosis not fully explained by traditional factors, while APS presents with thrombosis and pregnancy morbidity. This work foregrounds diagnostic criteria updates for APS and emphasizes that the relationship between SLE and APS is complex, with implications for prognosis and survival when these conditions co-occur.

(Gerosa et al., 2016) extend the discussion to the neurological domain, noting that SLE often features neuropsychiatric involvement and that antibodies directed at nuclear components reflect broader autoimmune activity. The article maps standard SLE treatments across severity and highlights Belimumab as a therapeutic option to reduce disease activity. For APS, it reiterates the requirement of persistent antiphospholipid antibodies and the distinction between primary APS and APS secondary to diseases such as SLE, while stressing long-term anticoagulation to prevent recurrence and detailing potential add-ons for refractory cases

(Dar et al., 2023) synthesize mechanisms linking SLE to premature cardiovascular disease, with particular attention to women of reproductive age. The review explicitly notes associations between SLE and APS, as well as the importance of timely diagnosis and comprehensive management to achieve remission, organ protection, and improved quality of life. By integrating cardiovascular risk into the differential, this article reinforces the need to consider APS within SLE-focused assessments and to tailor interventions accordingly

(Hamsho et al., 2024) contribute a case-based perspective on the diagnostic complexity when ANA-negative SLE presents with APS features, evidenced by an atypical atrial thrombus. This report illustrates how APS can complicate an SLE phenotype and highlights the ongoing relevance of recognizing thrombotic risk across the spectrum of SLE presentations, even when serologic markers are inconclusive.

(Bernardi et al, 2024) provide a broader narrative on cardiovascular complications in APS, detailing pathogenesis, laboratory criteria (including lupus anticoagulant, anti-B2-glycoprotein I, and anticardiolipin antibodies), and the interplay between primary APS and APS associated with SLE. The article emphasizes that half of SLE patients may manifest APS features, and it outlines evolving diagnostic criteria and therapeutic strategies, including anticoagulation and Immunosuppressive approaches, in older adults where cardiovascular risk is particularly pertinent

Collectively, these works map a trajectory from recognizing the coexistence and shared risk profiles of SLE and APS, through mechanistic and therapeutic considerations, to practical diagnostic and management implications across diverse patient populations. They emphasize that distinguishing features both serologic and clinical-must be integrated within a framework that acknowledges overlapping etiologies, shared vascular risk, and the need for individualized treatment strategies to optimize outcomes in differential diagnosis of systemic connective tissue diseases

METHODS

This review was conducted using a structured narrative methodology. Data were obtained from standard rheumatology textbooks, peer-reviewed journals, international classification criteria, and consensus guidelines published by recognized bodies such as the American College of Rheumatology (ACR), European League Against Rheumatism (EULAR), and International Society on Thrombosis and Haemostasis (ISTH).

Literature searches were performed using key terms including systemic connective tissue diseases, systemic lupus erythematosus, antiphospholipid syndrome, autoimmune rheumatic diseases, and differential diagnosis. Articles published in English were included, with emphasis on original research, systematic reviews, and clinical guidelines. Clinical observations and diagnostic reasoning commonly used in internal medicine and rheumatology practice were integrated to enhance practical applicability.

Systemic Lupus Erythematosus (SLE)

SLE is a chronic, relapsing-remitting autoimmune disease with a strong female predominance and variable clinical expression. It is characterized by loss of immunological tolerance to nuclear antigens, resulting in autoantibody production and immune complex deposition.

Key Clinical Features

Constitutional symptoms: fatigue, fever, weight loss

Musculoskeletal: symmetrical non-erosive arthritis

Cutaneous: malar rash, photosensitivity, discoid lesions

Renal: lupus nephritis (proteinuria, hematuria, casts)

Neurological: seizures, psychosis, cognitive dysfunction

Hematological: anemia, leukopenia, thrombocytopenia

Immunological Profile

ANA (high sensitivity)

Anti-dsDNA (disease activity marker)

Anti-Smith (high specificity)

Low complement levels (C3, C4)

Antiphospholipid Syndrome (APS)

APS is an autoimmune thrombotic disorder defined by the presence of antiphospholipid antibodies associated with vascular thrombosis and/or pregnancy morbidity. It may occur as a primary condition or secondary to SLE.

Diagnostic Challenges and Overlap

Approximately 30–40% of patients with SLE have antiphospholipid antibodies, and a subset develop full-blown APS. Distinguishing lupus nephritis from renal infarction due to APS is clinically crucial, as management strategies differ significantly.

Misdiagnosis may lead to inappropriate immunosuppression or inadequate anticoagulation, resulting in irreversible organ damage.

RESULTS

Analysis of the available literature demonstrates that SCTDs share overlapping clinical manifestations such as fatigue, arthralgia, fever, rash, Raynaud phenomenon, and multisystem involvement. However, careful assessment of disease onset, organ predominance, immunological markers, and disease course allows differentiation.

Systemic lupus erythematosus is distinguished by immune complex-mediated pathology, high titers of anti-double stranded DNA and anti-Smith antibodies, complement consumption, and fluctuating disease activity. In contrast, antiphospholipid syndrome is primarily characterized by a hypercoagulable state resulting from persistent antiphospholipid antibodies, leading to vascular thrombosis and pregnancy morbidity.

The coexistence of APS with SLE further complicates diagnosis, requiring precise interpretation of laboratory tests and clinical events. Differentiation from other connective tissue diseases such as rheumatoid arthritis, systemic sclerosis, polymyositis, mixed connective tissue disease, and vasculitides relies on integrated clinical and immunological evaluation.

DISCUSSION

Overview of Systemic Connective Tissue Diseases

Systemic connective tissue diseases are autoimmune disorders in which immune dysregulation leads to inflammation and damage of connective tissues, blood vessels, and internal organs. These conditions include systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, polymyositis, dermatomyositis, Sjögren syndrome, mixed connective tissue disease, and antiphospholipid syndrome.

The diagnostic challenge arises because early manifestations are often nonspecific and overlap across diseases. Fever, weight loss, malaise, arthralgia, and skin changes may precede definitive diagnostic markers by months or years.

The differential diagnosis of systemic connective tissue diseases (SCTDs) remains one of the most complex and intellectually demanding areas in clinical medicine. These disorders share a common autoimmune basis, multisystem involvement, and fluctuating clinical courses, which often leads to diagnostic uncertainty, especially in early or incomplete disease states. Systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) exemplify this complexity due to their heterogeneous presentations, frequent overlap with other rheumatologic conditions, and potential coexistence within the same patient.

Diagnostic Complexity of Systemic Connective Tissue Diseases

A fundamental challenge in diagnosing SCTDs lies in the nonspecific nature of early symptoms. Patients commonly present with fatigue, arthralgia, fever, rash, or laboratory abnormalities such as cytopenias, which are not pathognomonic for any single disease. These manifestations may precede the appearance of disease-specific autoantibodies by months or even years. Consequently, clinicians often face difficulty in distinguishing evolving SLE from other inflammatory, infectious, malignant, or autoimmune conditions.

Another critical factor is the dynamic evolution of autoimmune diseases. A patient initially classified as having undifferentiated connective tissue disease may later fulfill criteria for SLE, mixed connective tissue disease, or systemic sclerosis. This emphasizes the importance of longitudinal follow-up and repeated clinical and immunological reassessment rather than reliance on a single time-point evaluation.

Systemic Lupus Erythematosus in Differential Diagnosis

SLE is considered the prototypical systemic autoimmune disease due to its broad spectrum of clinical and immunological features. The disease can mimic almost any medical condition, earning its historical description as “the great imitator.”

Distinction from Other Connective Tissue Diseases

Differentiating SLE from rheumatoid arthritis (RA) is a frequent clinical challenge, particularly when arthritis is the predominant manifestation. While both conditions may present with symmetrical polyarthritis, SLE arthritis is typically non-erosive, lacks joint deformity in early stages, and is associated with systemic features such as photosensitivity, oral ulcers, and renal involvement. In contrast, RA is characterized by progressive erosive joint disease and absence of immune complex-mediated organ damage.

Similarly, SLE must be differentiated from systemic sclerosis when skin changes and Raynaud phenomenon dominate the clinical picture. Unlike systemic sclerosis, SLE rarely produces diffuse skin thickening or severe fibrotic organ involvement. Immunologically, the presence of anti-double stranded DNA and anti-Smith antibodies strongly supports SLE, whereas anti-topoisomerase I and anti-centromere antibodies suggest systemic sclerosis.

In patients with muscle weakness and elevated muscle enzymes, differentiation from polymyositis or dermatomyositis is essential. Myositis-specific antibodies, electromyography findings, and muscle biopsy help establish the correct diagnosis, as true inflammatory myopathy is relatively uncommon in isolated SLE.

Role of Immunological Markers in Differential Diagnosis

Autoantibody testing plays a central role in differentiating SCTDs; however, interpretation requires caution. Antinuclear antibodies (ANA) are highly sensitive for SLE but lack specificity and may be present in other autoimmune diseases, chronic infections, malignancies, and even healthy individuals. Therefore, ANA positivity alone should never be considered diagnostic.

Anti-dsDNA and anti-Smith antibodies provide greater specificity for SLE and correlate with disease activity and organ involvement, particularly lupus nephritis. Complement consumption further supports immune complex-mediated pathology and helps distinguish active SLE from non-inflammatory conditions.

In contrast, antiphospholipid antibodies do not indicate inflammatory tissue damage but rather a prothrombotic state. Their presence in the absence of clinical thrombosis does not establish APS, highlighting the necessity of integrating clinical events with laboratory findings.

Antiphospholipid Syndrome as a Distinct Entity

Antiphospholipid syndrome represents a unique autoimmune disorder in which the immune system induces a hypercoagulable state rather than direct inflammatory organ damage. This fundamental difference distinguishes APS from most other SCTDs and has profound therapeutic implications.

Differentiation from Other Thrombotic Disorders

APS must be carefully differentiated from other causes of thrombosis such as disseminated intravascular coagulation (DIC), thrombotic thrombocytopenic purpura (TTP), heparin-induced thrombocytopenia (HIT), and inherited thrombophilias. Unlike DIC, APS does not involve widespread consumption of clotting factors, and coagulation profiles are typically normal despite paradoxical prolongation of clotting tests due to lupus anticoagulant.

In contrast to TTP, APS lacks severe microangiopathic hemolytic anemia and neurological deterioration associated with ADAMTS13 deficiency. Persistence of antiphospholipid antibodies over time remains a defining feature that differentiates APS from transient antibody positivity seen during infections or drug exposure.

Overlap Between SLE and APS

One of the most clinically significant challenges is the frequent coexistence of APS and SLE. A substantial proportion of SLE patients harbor antiphospholipid antibodies, and a subset develops full clinical APS. In such cases, organ damage may result from either inflammatory immune complex deposition or thrombotic occlusion, making diagnostic precision essential.

For example, renal impairment in an SLE patient may arise from lupus nephritis or from renal vascular thrombosis due to APS. Histopathological examination becomes crucial, as management differs markedly: immunosuppression is required for lupus nephritis, whereas long-term anticoagulation is mandatory for APS-related thrombosis.

Similarly, neuropsychiatric manifestations in SLE may be inflammatory, ischemic, or mixed in origin. Failure to identify APS-related cerebral thrombosis may result in undertreatment and recurrent ischemic events.

Importance of Classification Criteria in Clinical Practice

Modern classification criteria, such as the 2019 EULAR/ACR criteria for SLE and the revised Sydney criteria for APS, have improved diagnostic consistency and research comparability. However, these criteria are primarily designed for classification rather than diagnosis. Rigid application without clinical judgment may lead to missed or delayed diagnoses, particularly in early or atypical disease presentations.

Experienced clinicians rely on pattern recognition, disease evolution, and response to therapy in addition to formal criteria. This underscores the importance of clinical expertise and multidisciplinary collaboration in managing SCTDs.

Therapeutic Implications of Accurate Differential Diagnosis

Accurate differentiation between SLE, APS, and other connective tissue diseases is not merely academic but directly impacts patient outcomes. Misclassification can lead to inappropriate therapy, such as unnecessary immunosuppression in isolated APS or failure to anticoagulate a patient with thrombotic risk.

Early recognition and targeted treatment reduce morbidity, prevent irreversible organ damage, and improve long-term survival. This is particularly relevant in young patients, where delayed diagnosis may have lifelong consequences.

Future Directions and Research Perspectives

Advances in immunology and molecular medicine are expected to refine the diagnostic approach to SCTDs. Novel biomarkers, genetic profiling, and improved imaging techniques may help distinguish inflammatory from thrombotic mechanisms of organ damage. Personalized medicine approaches may eventually replace rigid disease categories, allowing treatment to be tailored to underlying pathogenic pathways rather than clinical labels alone.

References

Franco, JS, Molano González, N., Rodriguez Jiménez, M., Acosta-Ampudia, Y. D. Mantilla, R., Amaya-Amaya, J., Rojas-Villarraga, A., and Anaya, J. M. The Coexistence of Antiphospholipid Syndrome and Systemic Lupus Erythematosus in Colombians.” (2014), nobunim.nih.gov.

Gerosa, M., Poletti, B., Pregnolato, F., Castellino, G., Lafronza, A., Silani, V., Ribaldi, P, Luigi Merani, P, and T. Merrill, J. “Antiglutamate Receptor Antibodies and Cognitive Impairment in Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus (2016). Ncbi.nlm.nih.gov

Dar, S., Koirala, S., Khan, A., Deepthi Bellary, M., V Patel, A, Mathew, B, Singh, R., Baigam, N Razzaq, W, U Abdin, Z., and Ahmed Khawaja, U. “A Comprehensive Literature Review on Managing Systemic Lupus Erythematosus: Addressing Cardiovascular Disease Risk in Females and its Autoimmune Disease Associations” (2023), ncbi.nlm.nih.gov

Hamsho, S., Alaswad, M., Makhlouf, Z., and Alcheikh, S. “Septal atrial thrombosis as a primary presentation of antiphospholipid syndrome in a patient with ANA-negative systemic lupus erythematosus: a case report (2024).ncbi.nlm.nih.goх

Bernardi, M., Spadafora, L. Andaloro, S., Piscitelli, A., Formaci, G., Intonti, C., Emanuele Fratta, A Hsu, C. E, Kazirod-Wolski, K., Metsovitis, T., Blondi-Zoccai, G., Sabouret, P, Marzetti, E, and Cacciatore, 5. “Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults.” (2024).ncbi.nlm.nih.gov